Human Icos Ligand (ICOSLG) Protein
1118€ (100 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Icos Ligand (ICOSLG) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx691069
tested applications
SDS-PAGE
Description
Icos Ligand (ICOSLG) protein is a recombinant Human protein expressed in HEK293 cells.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Icos Ligand (ICOSLG) |
| Host | HEK293 cells |
| Assay Type | Activity: Not tested Sequence Fragment: Met1-Pro283 Tag: C-terminal Fc tag |
| Origin | Human |
| Observed MW | 56.2 kDa |
| Expression | Recombinant |
| Purity | 97.2+1.4% (SDS-PAGE) |
| Size 1 | 100 µg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Buffer | Prior to lyophilization: Sterile PBS, pH 7.4. |
| Availability | Shipped within 5-15 working days. |
| Storage | Storage: Store lyophilized between -20 °C and -80°C. Stability: Stable when stored reconstituted at 2-8°C for up to 1 week. Reconstituted aliquots are stable at -20°C for up to 3 months. Shelf Life: 12 months. |
| Dry Ice | No |
| UniProt ID | O75144-1 |
| Alias | CRIg,Z39IG,Protein Z39Ig |
| Background | Protein ICOSLG |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Endotoxin Level: < 1.0 EU per µg (LAL method). |
Descripción
V-set and immunoglobulin domain containing 4 (VSIG4) is a complement receptor and immune checkpoint protein that primarily functions as an inhibitory molecule in macrophages and antigen-presenting cells. As a negative regulator of T-cell activation, VSIG4 suppresses immune responses by binding to complement components, thereby reducing inflammation and preventing tissue damage in autoimmune and inflammatory conditions. Its immune-inhibitory properties make VSIG4 a potential target for immune modulation therapies, particularly in autoimmune diseases and cancer immunotherapy. In the tumor microenvironment, VSIG4 expression on macrophages is associated with immune evasion, as it inhibits T-cell-mediated anti-tumor responses. Elevated VSIG4 levels have been linked to poor prognosis in several cancers, including hepatocellular carcinoma and melanoma. Beyond its role in immunity, VSIG4 is implicated in metabolic processes, as it interacts with lipid metabolism pathways in macrophages, influencing foam cell formation in atherosclerosis. Therapeutic strategies targeting VSIG4 are being explored to enhance anti-tumor immunity or regulate excessive inflammation, highlighting its significance as a multifunctional immune regulatory molecule.
Related Products
Human ICOSLG (ICOS ligand) ELISA Kit
Ver Producto
Mouse Icoslg (ICOS ligand) ELISA Kit
Ver Producto